March 3, 2020 / 5:49 PM / a month ago

BRIEF-Genkyotex's Setanaxib Improves Immunotherapy Including Checkpoint Inhibitors In Multiple Preclinical Cancer Models

March 3 (Reuters) - GENKYOTEX SA:

* GENKYOTEX’S SETANAXIB SIGNIFICANTLY IMPROVES IMMUNOTHERAPY INCLUDING CHECKPOINT INHIBITORS IN MULTIPLE PRECLINICAL CANCER MODELS

* GENKYOTEX SA ANNOUNCED TODAY THAT SETANAXIB, COMPANY’S NOX1 AND NOX4 INHIBITOR, WAS SHOWN TO SIGNIFICANTLY IMPROVE IMMUNOTHERAPY IN MULTIPLE PRECLINICAL CANCER MODELS

* DATA SUGGEST POSSIBILITY OF USING SETANAXIB IN COMBINATION WITH MULTIPLE TYPES OF IMMUNOTHERAPIES TO ENHANCE TREATMENT RESPONSES

* MULTIPLE PUBLICATIONS WITH SETANAXIB AND OTHER GENKYOTEX MOLECULES HIGHLIGHT STRONG INTEREST FOR NOX THERAPIES AND GENKYOTEX COMPOUNDS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below